Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln

Jasper Therapeutics

14/08/2026 16:12

Overview
US biotech firm's fiscal Q2 net loss per share was $0.10, beating analyst expectations
Company completed acquisition of Kira Pharmaceuticals in July, expanding clinical portfolio
PIPE financing raised $132 mln in gross proceeds to support operations through 2028

Outlook
Company expects interim data from KP-104 Phase 2 basket trial in Q4 2026
Jasper expects to announce next steps for KP-104 in PNH in H1 2027
Company believes current cash will fund operations through H2 2028

Result Drivers
PIPE FINANCING - Co raised $132 mln in gross proceeds through private placement to support operations through 2028
PORTFOLIO EXPANSION - Acquisition of Kira Pharmaceuticals expanded clinical pipeline and resources, per CEO Jeet Mahal
PIPELINE ADVANCEMENT - Co plans to advance KP-104, briquilimab, and KP-701 in multiple indications, per company update

Company press release: ID:nGNX1G647C

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.10
$0.35 (6 Analysts)
Q2 Net Loss
 
$2.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Jasper Therapeutics, Inc. is $6.00, about 595.2% above its August 13 closing price of $0.86

Reuters Recommended Reads
Aug 14 - Quince Therapeutics Q2 net loss widens on acquisition charges
Aug 12 - AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended
Aug 12 - Annexon Biosciences Q2 net loss widens, cash runway extended

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)